Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
Diseases and Conditions Researched
What is the purpose of this trial?People who have smoldering multiple myeloma do not have symptoms but are at risk for progressing to active multiple myeloma. Multiple myeloma is a cancer of the plasma cell, which is an important part of the immune system. People with active multiple myeloma generally require treatment. However, there are currently no approved therapies for smoldering multiple myeloma. The purpose of this study is to determine whether or not an investigational drug is effective and safe in treating people with high risk smoldering myeloma. The name of this investigational drug is elotuzumab. Elotuzumab is a manufactured protein directed against a target found on multiple myeloma cells. Elotuzumab was observed to kill myeloma cells in laboratory studies.
Click here for detailed participation information for this trial.
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.